Related Experiment Video
Updated: Jul 6, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Natalizumab: A new treatment for relapsing remitting multiple sclerosis
1Department of Neurology, St. Vincent’s University Hospital, Dublin Ireland.
Therapeutics and Clinical Risk Management
|March 25, 2008
Summary
Natalizumab effectively treats relapsing remitting multiple sclerosis (RRMS) by reducing relapses and disability progression. While beneficial, potential risks like progressive multifocal leukoencephalopathy (PML) require careful consideration.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Relapsing remitting multiple sclerosis (RRMS) is a chronic autoimmune disease affecting the central nervous system.
- Current disease-modifying therapies aim to reduce disease activity and disability progression.
Purpose of the Study:
- To evaluate the efficacy and safety of natalizumab, a humanized monoclonal antibody, in treating RRMS.
- To assess natalizumab's impact on relapse rates, disability progression, and MRI lesion activity.
Main Methods:
- Phase 3 clinical trials were conducted to compare natalizumab monotherapy and combination therapy with interferon (IFN) beta-1a against placebo or IFN beta-1a alone.
- Key outcome measures included annualized relapse rate (ARR), sustained disability progression, and T2-hyperintense and Gd+ lesions on MRI.
Main Results:
- Natalizumab monotherapy significantly reduced ARR by 68% and risk of disability progression by 42% compared to placebo over 2 years.
- Natalizumab also markedly decreased T2-hyperintense lesions by 83% and Gd+ lesions by 92%.
- Combination therapy with IFN beta-1a reduced ARR by 55% and disability progression by 24% versus IFN beta-1a alone.
Conclusions:
- Natalizumab demonstrates significant efficacy in reducing disease activity and disability progression in RRMS patients.
- Its use is supported for RRMS with high disease activity or rapidly evolving severe disease, considering potential risks such as progressive multifocal leukoencephalopathy (PML).
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...